Restoring Life After Limb-Loss
NeuroX Innovations
Limb loss does not end at the residual limb.
After an amputation, the sensory and motor pathways that once served the missing limb do not simply disappear. The nerves, spinal pathways, and areas of the brain associated with that limb remain active and coninue to send, receive, and anticipate signals.
When those signals no longer align, the result can be pain, discomfort, or other sensations that feel as though they are coming from a limb that is no longer there. This is known as Phantom Limb Syndrome.
The experience is real, common, and often difficult to treat. Current options are largely addictive pharmaceuticals or invasive surgical implants.
NeuroX is developing a non-invasive, closed-loop neuromodulation platform designed specifically to address the symptoms of Phantom Limb Syndrome. By combining intelligent sensing with personalized neuromodulation technology, our goal is to provide people with limb loss a new path toward lasting relief and an improved quality of life.
Understanding Phantom Limb Pain
What is happening?
When a limb is amputated, the nerves and areas of the brain that once controlled and received sensation from it remain. These systems continue to send and expect signals, even though the limb is no longer present.
When the expected and received signals no longer match, most people experience pain that feels as though it is coming directly from the missing limb.
The experience can vary significantly from person to person. It may feel like burning, cramping, shooting, stabbing, tingling, or pressure. Some people describe a missing hand or foot as feeling clenched, twisted, or trapped in an uncomfortable position.
Symptoms may remain constant or come and go without warning. Even people with similar amputations can have very different experiences.
It is common.
Phantom limb pain affects a significant portion of people living with limb loss. For many, the symptoms can interfere with sleep, mobility, emotional well-being, and daily life.
It is not imagined.
Although the pain may feel as though it is coming from a limb that is no longer physically present, the pain itself is real. Phantom limb pain is a recognized medical condition associated with changes throughout the peripheral and central nervous systems.
Treatment options remain limited.
Many people are treated with medication, rehabilitation, injections, or surgical procedures. While these approaches may help some patients, they are not always effective, sustainable, or appropriate for long-term use.
NeuroX is working to create an alternative: a wearable, non-pharmaceutical system designed specifically for the complex neurological processes associated with Phantom Limb Syndrome.
Speak with your care team.
The information provided on this website is for educational purposes only and is not intended to replace medical advice, diagnosis, or treatment. Anyone experiencing phantom limb pain or other symptoms following limb loss should speak with a qualified healthcare professional.
Our Team
NeuroX is operated by a committed team with deep expertise across all executive functions.
Jordan Doles is the founder and chief executive officer of NeuroX Innovations and the originator of its core technologies. With an academic background in cell and molecular neuroscience, Jordan conceived NeuroX’s neuromodulation approach and is first-named inventor across the company’s patent portfolio. Since founding the company in 2022, he has recruited a multidisciplinary leadership team, built a board of seasoned medical-device operators, and guided NeuroX from concept through advanced functional prototypes and onto an FDA De Novo pathway. As CEO, Jordan sets company vision and strategy, leads capital formation and investor relations, and serves on the Board of Directors. His commitment to NeuroX is deeply personal, grounded in a longstanding connection to limb loss, and continues to shape the company’s focus on improving quality of life for the amputee community.
Life-science executive with more than 15 years building and operating early-stage bioscience companies, and more than $40M raised across venture, angel, private-equity, and non-dilutive sources. He is Founder and fractional CEO of Validus Cellular Therapeutics, former COO of Sharklet Technologies (acquired 2017), former VP of Research at ForCast Ortho where he served as an NSF SBIR principal investigator, and former Director of Product Development at MuscleSound, where he led a software-as-a-medical-device transition. He chaired the Colorado Bioscience Association board from 2024 to 2025. He holds a PhD in Microbiology from the University of Nebraska and an MBA in Finance from CU Denver. He leads finance, FP&A, operations, and capital strategy.
Adam is a MedTech leader with a career of roughly 30 years, including 20 years focused on medical-device software and hardware systems, including software as a medical device. He was co-founder, CEO, and later CTO of Ortho Kinematics, where he raised $10M in venture capital as CEO and supported an additional $35M as CTO, secured $13M in strategic investment from Medtronic and NuVasive, led more than five 510(k) clearances, and managed FDA inspections and ISO 13485 and 62304 conformance. He later served as VP of Business Development at Baxter, overseeing a $5B portfolio, and Senior Director of Business Development at Medtronic on an AI-based clinical platform. He holds a B.S. in Honors Electrical Engineering from UT Austin. He brings digital-health architecture, IP stewardship, and business-development depth.
Laura is a global medical-device marketing leader with more than 20 years of upstream and downstream experience. As a Vice President and Global Marketing Leader at W.L. Gore and Associates, she led an organization of 70 across five regions for marquee brands including VIABAHN, CARDIOFORM, and SEAMGUARD, driving more than 10% year-over-year growth, and earlier led strategic marketing for a $1.5B business unit at Baxter Healthcare. She holds an MBA from USC and a B.S. in Quality Engineering. She leads brand strategy, positioning, voice-of-customer translation, and go-to-market planning for the NXI portfolio.
Alek is a medical-device development engineer with a track record across startups and large manufacturers. He was lead product-development engineer at Aspero Medical, advancing a balloon-overtube device to a successful 510(k) submission, with prior roles at Nordson Medical on thoracic stent-graft delivery systems, Medtronic on bone-conduction hearing devices, and CB Tech Ventures on an orthopedic implant. He holds an M.S. and B.S. in Mechanical Engineering with a biomedical emphasis from CU Boulder. He owns design controls, verification and validation, voice-of-customer, CAD, and design-for-manufacturability.
Allison is a former FDA reviewer in the Center for Devices and Radiological Health, Office of Device Evaluation, and a recognized biocompatibility specialist under ISO 10993. She holds a PhD in Neuroscience from Stanford, is Regulatory Affairs Certified, and is a Fellow of the Regulatory Affairs Professionals Society. She is a Senior Regulatory Strategist at DuVal and Associates and CEO of Bluestocking Health, with extensive De Novo, 510(k), PMA, IDE, Breakthrough Device, and Pre-Submission experience, and is a published author on FDA regulation of energy-based therapy devices and digital therapeutics. She leads NeuroX’s De Novo and Breakthrough Device strategy.
Senior market-access executive with a JD/MBA and an MSc in Health Economics from the London School of Economics. At Cala Health he built market-access and HEOR strategy for a non-invasive wearable neuromodulation therapy, the closest direct analogue to NXI Pulse, securing new HCPCS codes and CMS payment and supporting a Series D round. He developed a Breakthrough Device submission at StoParkinson and led global payer strategy at Abbott, driving more than $3.5B in sales across 33 markets, as well as at Novartis and Alcon, and most recently served as Global Head of Market Access at Saluda Medical. He leads coding, coverage, and payment strategy.
Stephanie is a clinical and medical-affairs executive with nearly 20 years concentrated in neuromodulation and chronic pain. She holds a PhD in Behavioral and Cellular Neuroscience. Her experience spans St. Jude Medical and Abbott on the spinal-cord and peripheral-nerve stimulation portfolio across IDE and post-approval studies, VP of Clinical and Medical Affairs at Spark Biomedical on non-invasive neurostimulation for opioid withdrawal, Medical Science Liaison for electroCore’s gammaCore vagus-nerve stimulator, and clinical leadership at PainTEQ and ImThera. She has authored clinical evaluation reports and IDE protocols and led multi-site study activation. She leads clinical evidence strategy and the company’s IRB-approved study.
Mike is a principal engineer with more than 40 years of medical-device engineering experience and inventor on more than 15 U.S. patents. He is owner of BOCS LLC, with deep expertise in electrosurgery, ultrasonics, infusion-pump, and medical-disposables design developed at ConMed, Baxter and Baxa on automated pharmacy filling systems, Team Medical, and Valleylab, where he worked on the first laparoscopic CUSA ultrasonic aspirator. He holds a B.S. in Mechanical Engineering from Rice. He leads mechanical design, materials selection, modeling, and verification programs.
Wes is the President of Spearhead Designs with more than 25 years in medical-device system architecture. His directly relevant work includes a knee and lower-back neuromuscular electrical-stimulation system spanning hardware, firmware, BLE wireless, mobile app, and therapy-pad electrode design, as well as a peripheral-nerve stimulator and the system architecture, design description, and verification and validation documentation for a De Novo submission. He holds a B.S. in Electrical Engineering from the Colorado School of Mines, where he was named Outstanding Graduating Senior. He is fluent in ISO 14971, ISO 13485, IEC 62304, and IEC 60601. He owns electronics, firmware, and the companion-app development.
ASQ-Certified Biomedical Auditor and owner of Anvis Consulting, with prior tenure as Senior Quality Engineer and Quality Manager at Baxter and Baxa. She brings deep design-control, design-history-file, verification-and-validation, and design-transfer experience, with hands-on support for FDA, ISO 13485, and MDSAP audits and 21 CFR 820 conformance across more than 25 device qualification programs. She leads the company’s quality management system and design-control framework.
Contact Us
"*" indicates required fields